Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec 16;65(1):e02039-20.
doi: 10.1128/AAC.02039-20. Print 2020 Dec 16.

Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy

George Sakoulas  1
Affiliations
Comment

Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy

George Sakoulas. Antimicrob Agents Chemother. .

Abstract

Given that it is unlikely that randomized clinical trials will yield answers for treating the most challenging bacteremic infections caused by methicillin-resistant Staphylococcus aureus, clinicians, microbiologists, and pharmacists will have to cooperate to discover novel ways to select successful individualized antimicrobial therapy for these patients. An example of such a strategy was demonstrated in the identification and utilization of imipenem/cilastatin plus fosfomycin to treat a particularly recalcitrant MRSA bacteremia and spinal abscess.

Keywords: MRSA; antimicrobial combinations; bacteremia.

PubMed Disclaimer

Comment on

References

    1. Nakamura I, Yamaguchi T, Aoki K, Miura Y, Sato S, Fujita H, Watanabe H. 2021. Imipenem plus fosfomycin as salvage therapy for vertebral osteomyelitis. Antimicrob Agents Chemother 65:e01746-20. doi: 10.1128/AAC.01746-20. - DOI - PMC - PubMed
    1. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Jr, Eliopoulos GM. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50:1581–1585. doi: 10.1128/AAC.50.4.1581-1585.2006. - DOI - PMC - PubMed
    1. Mishra NN, Yang SJ, Chen L, Muller C, Saleh-Mghir A, Kuhn S, Peschel A, Yeaman MR, Nast CC, Kreiswirth BN, Crémieux AC, Bayer AS. 2013. Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One 8:e71151. doi: 10.1371/journal.pone.0071151. - DOI - PMC - PubMed
    1. McCreary EK, Kullar R, Geriak M, Zasowski EJ, Rizvi K, Schulz LT, Ouellette K, Vasina L, Haddad F, Rybak MJ, Zervos MJ, Sakoulas G, Rose WE. 2020. Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis 7:ofz538. doi: 10.1093/ofid/ofz538. - DOI - PMC - PubMed
    1. Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, Yu M, Vasina L, Ouellette K, Zervos M, Nizet V, Sakoulas G. 2019. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63:e02483-18. doi: 10.1128/AAC.02483-18. - DOI - PMC - PubMed

MeSH terms